---
title: "Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291980522.md"
description: "Vivos Therapeutics completed a $2.1 million private placement (PIPE) with V-Co Investors 4 and Bigger Capital Fund. The deal involved 3,608,496 units at $0.582 each, comprising Series A Convertible Preferred Stock and warrants. The company received $1.0 million in cash, with the remainder from converted bridge notes. Additionally, Vivos entered into a Registration Rights Agreement to file a resale registration statement within 45 days."
datetime: "2026-07-07T21:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291980522.md)
  - [en](https://longbridge.com/en/news/291980522.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291980522.md)
generator: "portal-rs"
---

# Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital

Vivos Therapeutics completed a private placement (PIPE) totaling approximately $2.1 million through a Securities Purchase Agreement with V-Co Investors 4 and Bigger Capital Fund. The financing comprised 3,608,496 units at $0.582 per unit, each with one share of Series A Convertible Preferred Stock and a warrant exercisable at $0.456 per share. The company received $1.0 million in cash at closing, and $1.0 million previously funded under a bridge note converted into the PIPE. In connection with the financing, Vivos also entered into a Registration Rights Agreement obligating it to file a resale registration statement within 45 days and seek effectiveness within 90 days, maintaining effectiveness until the securities are freely tradable.

**Agreement 1: Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital**

-   **Agreement type**: Securities Purchase Agreement for private placement (PIPE) of Units (Series A Preferred and Warrants)
-   **Counterparty**: V-Co Investors 4; Bigger Capital Fund
-   **Signed / Effective**: Jun 30 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Enhance liquidity and fund working capital

**Agreement 2: Vivos Therapeutics Grants Resale Registration Rights to PIPE Investors**

-   **Agreement type**: Registration Rights Agreement for resale of conversion and warrant shares
-   **Counterparty**: V-Co Investors 4; Bigger Capital Fund
-   **Signed / Effective**: Jun 30 2026 / same
-   **Duration / Termination**: Until all registrable securities are freely tradable
-   **Reason**: Provide investor liquidity and facilitate resale

Original SEC Filing: Vivos Therapeutics, Inc. \[ VVOS \] - 8-K - Jul. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [VVOS.US](https://longbridge.com/en/quote/VVOS.US.md)

## Related News & Research

- [Vivos reports peer-reviewed publication detailing PrecisionGel polymer platform release properties](https://longbridge.com/en/news/297910391.md)
- [Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep testing, treatment center](https://longbridge.com/en/news/297327635.md)
- [FingerMotion prices registered direct offering at $0.24 per share with pre-funded warrants](https://longbridge.com/en/news/298075887.md)
- [DynaResource Raises $3.0 Million in Private Placement of Units With Warrants; Voting Pacts Secured](https://longbridge.com/en/news/297832184.md)
- [Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE](https://longbridge.com/en/news/297896887.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**